Back to Back Issues Page
Resurfacing Damaged Retinas
January 29, 2013

Resurfacing Damaged Retinas

"The gains in visual acuity we reported for our first two patients have persisted for nearly 18 months now. In addition to measuring visual acuity, the clinical sites have been providing us with fundus photographs and other evidence showing that the transplanted RPE cells engrafted in appropriate space and are apparently resurfacing the damaged retinas in our patients," states Gary Rabin, the CEO of Advanced Cell Technology (ACT) in his January 2013 Blog.

Many readers have asked for an update on what is happening in the stem cells and macular degeneration studies. As a recap, Advanced Cell Technology is a U.S. bio-tech company that is sponsoring clinical trials treating patients with advanced dry macular degeneration and Stargardt's disease with embryonic retinal pigment epithelial cells (RPE).

Unlike many other stem cell studies, ACT uses a patented technology whereby they can obtain the stem cells without harming or destroying the embryo.

After 18 months the company is able to make reports on safety, which is the main focus of a Phase I clinical trial, but observations on visual acuity improvements as well as engraftment have also been noted.

As of January 2013 changes in the eligibility requirements for Stargardts disease and dry macular degeneration patients have been made:

Get the latest update here: Resurfacing Damaged Retinas 

If you are a Facebook Fan please hit the "like" button in the upper left hand corner.

Thanks so much for subscribing to Macular Degeneration News.

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page